Chemokine and cytokine inflammatory networks

Chemokine and cytokine inflammatory networks represent a complex system of small signaling proteins that mediate and regulate immunity, inflammation, and hematopoiesis [1]. Cytokines, such as interleukins and interferons, act as chemical messengers to coordinate the immune response, while chemokines specifically direct the migration of immune cells to sites of injury or infection via chemotaxis [2]. These networks function through intricate autocrine, paracrine, and endocrine signaling pathways that involve binding to specific cell-surface receptors [3]. Dysregulation of these networks, characterized by overproduction or persistent signaling, is a hallmark of numerous pathological conditions, including autoimmune diseases, chronic inflammatory disorders, and cancer [3]. Therapeutic intervention often involves targeting specific nodes within these networks to restore homeostasis [4]. Common strategies include neutralizing monoclonal antibodies against tumor necrosis factor (TNF) or interleukin-6 (IL-6), and small molecule antagonists of chemokine receptors like CCR5 and CXCR4 [4]. Additionally, intracellular signaling inhibitors, such as Janus kinase (JAK) inhibitors, are used to block the downstream effects of multiple cytokines simultaneously [5]. While highly effective in treating conditions like rheumatoid arthritis and inflammatory bowel disease, modulating these networks carries risks of systemic immunosuppression and increased susceptibility to opportunistic infections [5]. References: [1] Dinarello, C. A. (2007). Eur J Immunol. [2] Turner, M. D., et al. (2014). Biochim Biophys Acta. [3] Zlotnik, A., & Yoshie, O. (2012). Immunity. [4] Feldmann, M. (2002). Nat Rev Immunol. [5] Kerschbaumer, A., et al. (2020). Ann Rheum Dis.

Other names

Cytokine-chemokine signalingInflammatory cytokine networkChemokine signaling pathwayImmune signaling networksCytokine-chemokine interactome

Therapeutic agents modulate these networks by neutralizing soluble ligands (cytokines or chemokines) to prevent receptor binding, competitively inhibiting cell-surface receptors, or blocking intracellular signal transduction pathways, such as the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, to suppress the inflammatory cascade [4, 5].